Asia-Pacific is attracting increased investor interest as a biotech hub, according to a new report by Bain & Company and several industry partners.

The report notes that geopolitical tensions and reduced US research funding are prompting global pharmaceutical companies to shift R&D strategies toward the region.

China remains the largest recipient, accounting for more than 75% of regional biotech venture capital and private equity flows since 2019, though markets like Singapore and South Korea are also seeing increased investment.

Singapore, which has invested heavily in its biotech ecosystem, is cited for its political neutrality, strong intellectual property protection, and regulatory alignment.

Other Asia-Pacific governments, such as those in South Korea, Japan, and India, have launched public funding initiatives to support early-stage biotech research and encourage private capital.

Late-stage biotech deal volumes in the region grew by 1.5x from 2019 to 2024, while early-stage funding declined, reflecting increased investor preference for mature projects.

The report highlights ongoing efforts across the region to attract talent and foster innovation.

🔗 Source: Bain & Company

🧠 Food for thought

1️⃣ Public funding fills critical early-stage gap as private capital shifts to safer bets

The Asia-Pacific biotech funding landscape reflects a clear risk bifurcation that governments are strategically addressing.

Private investors are increasingly moving toward later-stage, lower-risk biotech assets, which has created funding gaps in early-stage research and development across the region1.

In response, public institutions have stepped in with substantial commitments: South Korea’s Korea Drug Development Fund allocated $1.6 billion across over 1,200 projects by 2030, while Japan deployed $366 million through its Bioventure Support Program.

This trend aligns with broader venture capital behavior where early-stage biotech funding declined at an 11% compound annual growth rate from 2019 to 2024, even as late-stage deal volumes grew 1.5 times during the same period.

The strategic public intervention highlights how governments are using targeted funding to maintain innovation pipelines that private markets might otherwise abandon due to heightened risk aversion.

2️⃣ Clinical trials data reveals concrete shift toward Asia-Pacific research dominance